<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
<channel>
<title><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></title>
<link><![CDATA[http://www.pinksheets.com/pink]]></link>
<image>
<url><![CDATA[http://www.pinksheets.com/content/doc/ps/logos/company-small.gif]]></url>
<title><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></title>
<link><![CDATA[http://www.pinksheets.com/pink]]></link>
</image>
<description><![CDATA[Pink OTC Markets - RSS Feed]]></description>
<copyright>Copyright 2009 - Pink OTC Markets</copyright>
<lastBuildDate>Thu, 02 Jul 2009 20:32:46 EDT</lastBuildDate>
<docs><![CDATA[http://www.rssboard.org/rss-specification]]></docs>
<item>
<title><![CDATA[Tesoro Distributors, Inc. (TSRD: Pink Quote) | Home Treasures, Inc. signs second dealer agreement]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=TSRD&newsId=15555]]></link>
<description><![CDATA[On July 2, 2009, Home Treasures Inc., a subsidiary of Tesoro Distributors, Inc. (TSRD/PK) (formerly IWT Tesoro Corporation) announced that it had completed an agreement to represent a manufacturer of marble building materials.&nbsp; The products will include fireplace facings, door and window surrounds, fountains, stairway treads and bulusters and colums.&nbsp; This relationship will also add washbasins, sinks and additional natural stone tiles to HomeTreasures product suite.&nbsp; These new products will be available&nbsp;through the company's web site at <A href="http://www.easyhomeupgrade.com">www.easyhomeupgrade.com</A>.&nbsp;&nbsp; Henry J. Boucher, the company's president said "The addition of these fine stone products moves the company closer to its goal of providing a full suite of stone products to enhance and beautify the residential and commerical investments of our customers".&nbsp;&nbsp;<br><br>Information concerning the company is available on our website at <A href="http://www.tesorodistributors.com">www.tesorodistributors.com</A> or by contacting us at PO Box 457, Wilton, CT 06897-0457]]></description>
<pubDate>Thu, 02 Jul 2009 14:50:28 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=TSRD&newsId=15555]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Tesoro Distributors, Inc.]]></category>
</item>
<item>
<title><![CDATA[Imperial Tobacco Group PLC (ITYBY: Pink Quote) | Director/PDMR Shareholding]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=ITYBY&newsId=15553]]></link>
<description><![CDATA[<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial">Imperial Tobacco Group <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:stockticker w:st="on">PLC</st1:stockticker> (the &#8220;Company&#8221;)<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial">The Company announces that it has received notice that one of its non-executive directors, Mr Bruno Bich, has purchased 102 American Depositary Shares (&#8220;ADSs&#8221;) each representing two 10p ordinary shares (&#8220;Ordinary Shares&#8221;) in the Company at a price of US$51.30 per ADS. <o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial">The purchase was made pursuant to an <span style="mso-bidi-font-weight: bold">irrevocable</span> mandate given by Mr Bich to his brokers under which they purchase ADSs each month equivalent in value to his net director&#8217;s fees.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial">Following this transaction Mr Bich&#8217;s holding is 377 Ordinary Shares and 999 ADSs in the Company.<o:p></o:p></span></P><P class=AODocTxt style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal; TEXT-ALIGN: left; mso-list: none" align=left><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"><o:p>&nbsp;</o:p></span></P><P class=AODocTxt style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal; TEXT-ALIGN: left; mso-list: none" align=left><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB"><o:p>&nbsp;</o:p></span></P><P class=AODocTxt style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal; TEXT-ALIGN: left; mso-list: none" align=left><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Trevor Williams<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial">Deputy Company Secretary<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P><P class=AODocTxt style="MARGIN: 12pt 0cm 0pt; TEXT-INDENT: 0cm; LINE-HEIGHT: normal; TEXT-ALIGN: left" align=left><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Copies of our announcements are available on our website www.imperial-tobacco.com<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-pagination: widow-orphan"><span style="FONT-SIZE: 11pt; FONT-FAMILY: Arial"><o:p>&nbsp;</o:p></span></P>]]></description>
<pubDate>Thu, 02 Jul 2009 11:05:03 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=ITYBY&newsId=15553]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Imperial Tobacco Group PLC]]></category>
</item>
<item>
<title><![CDATA[GenX Corp. (GNXO: Pink Quote) | Suspension of Trading]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=GNXO&newsId=15552]]></link>
<description><![CDATA[<strong><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNITED STATES OF AMERICA<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before the<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SECURITIES AND EXCHANGE COMMISSION</strong><br><br>SECURITIES EXCHANGE ACT OF 1934 <br>RELEASE NO. 60227 / July 2, 2009<br><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>SEC SUSPENDS TRADING IN THE SECURITIES OF GENX CORPORATION</strong><br><br>The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), of trading of the securities of GenX Corporation (&#8220;GenX&#8221;) at 9:30 a.m. EDT on July 2, 2009, and terminating at 11:59 p.m. EDT on July 16, 2009.<br><br>The Commission temporarily suspended trading in the securities of GenX because of questions that have been raised about the accuracy and adequacy of publicly disseminated information appearing in stock promotional materials, and elsewhere, concerning among other things, the company&#8217;s purported partnerships and other relationships with certain individuals and entities.<br><br>The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.<br><br>Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not it has complied with the rule, it should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, it should refrain from entering quotations relating to GenX&#8217;s securities until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation that is in violation of the rule, the Commission will consider the need for prompt enforcement action.<br><br>If any broker, dealer or other person has any information which may relate to this matter, David R. Herman, Senior Counsel, Division of Enforcement, should be telephoned at<br>(202) 551-4588.]]></description>
<pubDate>Thu, 02 Jul 2009 09:30:00 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=GNXO&newsId=15552]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[GenX Corp.]]></category>
</item>
<item>
<title><![CDATA[Eastern Star Gas Ltd. (ESGLY: Pink Quote) | Santos Acquires Project & Equity Interests]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=ESGLY&newsId=15551]]></link>
<description><![CDATA[<a href="http://clients.weblink.com.au/clients/easternstar/article.asp?asx=ESG&amp;view=2556026">Santos Acquires Project &amp; Equity Interests</a>]]></description>
<pubDate>Thu, 02 Jul 2009 05:05:31 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=ESGLY&newsId=15551]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Eastern Star Gas Ltd.]]></category>
</item>
<item>
<title><![CDATA[EnviroMission Ltd. (EVOMY: Pink Quote) | Land Applications Filed for First US Solar Tower Development Sites]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=EVOMY&newsId=15550]]></link>
<description><![CDATA[<P class=CM5 style="MARGIN: 0cm 0cm 6.25pt 7.1pt"><font size=3><span style="mso-spacerun: yes">&nbsp;&nbsp;</span><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><v:shapetype id=_x0000_t75 stroked="f" filled="f" path="m@4@5l@4@11@9@11@9@5xe" o:preferrelative="t" o:spt="75" coordsize="21600,21600"><v:stroke joinstyle="miter"></v:stroke><v:formulas><v:f eqn="if lineDrawn pixelLineWidth 0"></v:f><v:f eqn="sum @0 1 0"></v:f><v:f eqn="sum 0 0 @1"></v:f><v:f eqn="prod @2 1 2"></v:f><v:f eqn="prod @3 21600 pixelWidth"></v:f><v:f eqn="prod @3 21600 pixelHeight"></v:f><v:f eqn="sum @0 0 1"></v:f><v:f eqn="prod @6 1 2"></v:f><v:f eqn="prod @7 21600 pixelWidth"></v:f><v:f eqn="sum @8 21600 0"></v:f><v:f eqn="prod @7 21600 pixelHeight"></v:f><v:f eqn="sum @10 21600 0"></v:f></v:formulas><v:path o:connecttype="rect" gradientshapeok="t" o:extrusionok="f"></v:path><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:lock aspectratio="t" v:ext="edit"></o:lock></v:shapetype><v:shape id=_x0000_i1025 style="WIDTH: 78.75pt; HEIGHT: 36.75pt" o:bullet="t" type="#_x0000_t75"><v:imagedata o:title="" src="file:///C:\DOCUME~1\rdavey\LOCALS~1\Temp\msohtml1\01\clip_image001.jpg"></v:imagedata></v:shape><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br></span></font><strong><span style="FONT-SIZE: 35pt; COLOR: #999999">MEDIA RELEASE </span></strong><v:shape id=_x0000_i1026 style="WIDTH: 90.75pt; HEIGHT: 66.75pt" type="#_x0000_t75"><v:imagedata o:title="" src="file:///C:\DOCUME~1\rdavey\LOCALS~1\Temp\msohtml1\01\clip_image003.jpg"></v:imagedata></v:shape></P><P class=Default style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><font size=3><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br></span>&nbsp;&nbsp;&nbsp;&nbsp;ASX Code:<span style="mso-spacerun: yes">&nbsp; </span>EVM<o:p></o:p></font></strong></P><P class=Default style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><font size=3><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp; </span><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:country-region w:st="on"><st1:place w:st="on">USA</st1:place></st1:country-region> OTC:<span style="mso-spacerun: yes">&nbsp;&nbsp; </span>EVOMY<o:p></o:p></font></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 18pt; TEXT-ALIGN: center; mso-pagination: none; mso-layout-grid-align: none; mso-line-height-rule: exactly" align=center><A name=OLE_LINK1><strong><span lang=EN-US style="FONT-SIZE: 16pt; FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><font color=#000000><span style="FONT-FAMILY: Times New Roman"><br>LAND APPLICATIONS FILED FOR FIRST US<o:p></o:p></span></font></span></strong></A></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 18pt; TEXT-ALIGN: center; mso-pagination: none; mso-layout-grid-align: none; mso-line-height-rule: exactly" align=center><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-SIZE: 16pt; FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">SOLAR TOWER DEVELOPMENT SITES <o:p></o:p></span></span></strong></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></strong></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="FONT-FAMILY: Times New Roman"><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">MELBOURNE, Australia, July 2/-- </span></strong></span><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">Land applications for two Solar Tower power station developments in the US southwest have been filed by global Solar Tower developer, EnviroMission Limited. <o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span style="FONT-FAMILY: Times New Roman"><st1:City w:st="on"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">Melbourne</span></st1:City><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"> based EnviroMission Limited, recently commenced operations in <st1:City w:st="on">Phoenix</st1:City> <st1:State w:st="on">Arizona</st1:State>, and established a 100% owned subsidiary, EnviroMission (USA) Inc., to lead <st1:PlaceName w:st="on">Solar</st1:PlaceName> <st1:PlaceType w:st="on">Tower</st1:PlaceType> development in the <st1:place w:st="on"><st1:country-region w:st="on">US</st1:country-region></st1:place> market.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">The drive for <st1:PlaceName w:st="on">Solar</st1:PlaceName> <st1:PlaceType w:st="on">Tower</st1:PlaceType> development in the <st1:country-region w:st="on">US</st1:country-region> is underpinned by the availability and acquisition of suitable land; each land application for 5,500 acres will meet the site development requirements for a single 200MW <st1:place w:st="on"><st1:PlaceName w:st="on">Solar</st1:PlaceName> <st1:PlaceType w:st="on">Tower</st1:PlaceType></st1:place> power station.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">The land applications with the Arizona State Land Department have been lodged for marginal land identified as ideal for <st1:place w:st="on"><st1:PlaceName w:st="on">Solar</st1:PlaceName> <st1:PlaceType w:st="on">Tower</st1:PlaceType></st1:place> development based on due diligence studies that indicate all critical development criteria, including meteorological and solar insulation parameters would be met and exceeded at both sites.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman"><span style="mso-spacerun: yes">&nbsp;</span><o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">Ownership surveys, completed in May 2009, informed both applications and cultural, archeological and environmental surveys are expected to be completed in July 2009.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">Identification of the sites will be disclosed when disclosure will not prejudice EnviroMission's competitive advantage in the land application process.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">EnvrioMission's Chief Executive, Roger Davey said &#8220;I&#8217;ve personally walked both sites in <st1:State w:st="on">Arizona</st1:State> and they tick all the boxes for <st1:place w:st="on"><st1:PlaceName w:st="on">Solar</st1:PlaceName> <st1:PlaceType w:st="on">Tower</st1:PlaceType></st1:place> power station development needs."<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">"The land is flat, the weather is ideally and consistently hot and both sites are in close proximity to transmission infrastructure.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">&#8220;The quality of the sites, and overall market and policy opportunities currently available to<span style="mso-spacerun: yes">&nbsp; </span>renewable energy developers in the US confirms EnviroMission&#8217;s decision to shift our Solar Tower development priority to that market&#8221; Mr. Davey said in support of the Arizona land applications.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">Ends. <o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></strong></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="FONT-FAMILY: Times New Roman"><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">About EnviroMission Limited</span></strong></span><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">EnviroMission is a renewable energy developer and innovator of commercially viable large-scale power generation technology using solar radiation for zero emissions electricity generation.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">More information about EnviroMission Limited can be found at: www.enviromission.com.au<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p><span style="FONT-FAMILY: Times New Roman">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><strong><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">Notes about forward-looking statements<o:p></o:p></span></span></strong></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><span style="FONT-FAMILY: Times New Roman">Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties.<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 11pt; mso-pagination: none; mso-layout-grid-align: none; mso-line-height-rule: exactly"><span style="FONT-FAMILY: Times New Roman"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as "estimates", "anticipates", "projects", "plans", "expects", "intends", "believes", "may", "should", and similar expressions and by the context in which they are used.<span style="mso-spacerun: yes">&nbsp; </span>Such statements are based upon current expectations of the company and speak only as of the date made.<span style="mso-spacerun: yes">&nbsp; </span>The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date when they are made.</span></span><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-SIZE: 16pt; FONT-FAMILY: TimesNewRomanPSMT; mso-bidi-font-family: TimesNewRomanPSMT">&nbsp;<o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 11pt; mso-pagination: none; mso-layout-grid-align: none; mso-line-height-rule: exactly"><span style="FONT-FAMILY: Times New Roman"><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: TimesNewRomanPSMT; mso-bidi-font-family: TimesNewRomanPSMT"><span style="mso-tab-count: 9">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT"><o:p></o:p></span></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><span style="FONT-FAMILY: Times New Roman"><span style="mso-bookmark: OLE_LINK1"><strong style="mso-bidi-font-weight: normal"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">Media Enquiries</span></strong></span><span style="mso-bookmark: OLE_LINK1"><span lang=EN-US style="FONT-FAMILY: ArialMT; mso-bidi-font-family: ArialMT">: Ms Kim Forte, Communications Manager, EnviroMission Limited, EnviroMission (<st1:country-region w:st="on"><st1:place w:st="on">USA</st1:place></st1:country-region>), Inc.<span style="mso-spacerun: yes">&nbsp; </span>+61414 690356 kforte@enviromission.com.au</span></span></span></P>]]></description>
<pubDate>Thu, 02 Jul 2009 00:46:03 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=EVOMY&newsId=15550]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[EnviroMission Ltd.]]></category>
</item>
<item>
<title><![CDATA[Bravura Solutions Ltd. (BRVSY: Pink Quote) | Bravura and i-Financial sign partner program agreement for anti-money laundering software supply]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=BRVSY&newsId=15549]]></link>
<description><![CDATA[<span lang=EN-US style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-AU; mso-bidi-language: AR-SA"><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center" align=center><strong><span style="FONT-FAMILY: 'Arial','sans-serif'"><font size=3>Bravura and i-Financial sign partner program agreement for <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></font></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center" align=center><strong><span style="FONT-FAMILY: 'Arial','sans-serif'"><font size=3>anti-money laundering software supply<o:p></o:p></font></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><strong style="mso-bidi-font-weight: normal"><span lang=EN-US style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><strong style="mso-bidi-font-weight: normal"><span lang=EN-US style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US"><o:p>&nbsp;</o:p></span></strong></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><font color=#000033><strong>Sydney, 2 July 2009 (ASX: BVA/OTCQX: BRVSY) &#8211; </strong>Bravura Solutions (Bravura) - a leading global supplier of wealth management applications and professional services has signed a partner program </font><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US">agreement with</span><span lang=EN-US style="FONT-SIZE: 9pt; COLOR: #333333; FONT-FAMILY: 'Trebuchet MS','sans-serif'"> </span><STRONG><span style="COLOR: #333333; FONT-FAMILY: 'Arial','sans-serif'">International Financial Systems Australia Pty Ltd, (i-Financial)</span></STRONG><span style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"> <span lang=EN-US>a company </span></span><span style="COLOR: #333333">specialising in providing software solutions, services and equipment to a variety of banks, credit unions and financial institutions worldwide</span><span style="COLOR: windowtext">,</span><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"> to supply anti-money laundering software to Bravura&#8217;s clients.<o:p></o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"><o:p>&nbsp;</o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="COLOR: windowtext">Anti-money laundering has become more heavily regulated in Australia following new legislation in December 2006<A style="mso-footnote-id: ftn1" href="https://www.otciq.com/otciq/member/#_ftn1" name=_ftnref1><span class=MsoFootnoteReference><span style="mso-special-character: footnote"><span class=MsoFootnoteReference><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-AU; mso-fareast-language: EN-AU; mso-bidi-language: AR-SA">[1]</span></span></span></span></A>, and as a consequence financial institutions are now required to more rigorously scrutinise their data.<o:p></o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="COLOR: windowtext"><o:p>&nbsp;</o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="COLOR: windowtext">i-Financial&#8217;s MLTrac anti-money laundering product</span><font color=#000033> </font><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US">delivers web-based compliance tools that together help identify, track and regulate potentially suspicious or illegal activities in respect to money laundering and the proceeds of crime.</span><span style="COLOR: windowtext"><o:p></o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"><o:p>&nbsp;</o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="COLOR: windowtext">&#8220;Due to the global nature of Bravura&#8217;s business, it</span><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US"> was important to choose a partner that has a presence in both Australia and the UK, and would be able to assist our clients in identifying and tracking suspicious transactions,&#8221; </span><span style="COLOR: windowtext">said Darren Stevens, Bravura&#8217;s Global Head of Product.<o:p></o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"><o:p>&nbsp;</o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US"><font face=Verdana>&#8220;</font></span><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'">Bravura continually searches for new and innovative ways to offer our clients the best the market has to offer. <span style="mso-spacerun: yes">&nbsp;</span>Outsourcing our anti-money laundering needs to a best of breed supplier, such as i-Financial, was the clear choice for our clients.<span style="mso-spacerun: yes">&nbsp; </span></span><span lang=EN-US style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US">We chose i-Financial because of its solid </span><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'">track record in providing responsive service, successful delivery and superior technical skills across a broad range of hardware, software and service offerings,&#8221; he said.</span><span lang=EN-US style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US"><o:p></o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-US style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US"><o:p>&nbsp;</o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'">MLTrac offers a modular approach tailored to provide the appropriate level of functionality for the defined level of risk and need of each entity.<o:p></o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'"><o:p>&nbsp;</o:p></span></P><P class=bodytext style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="COLOR: windowtext">Its online capabilities capture data and relevant documentation from new customers, checking it against a range of government watch lists and electronic verification services. <span style="mso-spacerun: yes">&nbsp;</span>The product automatically detects changes in the lists and continuously sweeps the existing customer database ensuring that all customers remain compliant. <span style="mso-spacerun: yes">&nbsp;</span>MLTrac can also link into third party providers. </span><span lang=EN-US style="COLOR: windowtext; mso-ansi-language: EN-US; mso-fareast-language: EN-US"><o:p></o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'"><o:p>&nbsp;</o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'">One of the modules, Know Your Customer (&#8220;KYC&#8221;), allows users to manage commencement and ongoing customer due diligence requirements, as well as providing a watch list checking engine to validate customers against persons of known interest. <span style="mso-spacerun: yes">&nbsp;</span>MLTrac also delivers an account monitoring module with flexible business rules to identify possible suspicious trends, and a transaction level monitoring module for identifying and investigating individual transactions as defined by the user. <o:p></o:p></span></P><P style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-GB style="FONT-SIZE: 10pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">&#8220;We are delighted to partner with Bravura to offer MLTrac to its client base,&#8221; said Chris Kelly, <span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>i-Financial&#8217;s Sales Director in Australia.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-weight: bold"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-weight: bold">&#8220;In choosing MLTrac, Bravura has gained the ability to assist its clients to </span><span style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">improve their internal disciplines, supplement their policies and procedures, and make a clear statement to authorities about their commitment to effective anti-money laundering controls,&#8221; he said.</span><span style="FONT-FAMILY: 'Arial','sans-serif'"><o:p></o:p></span></P><DIV style="mso-element: footnote-list"><br><HR align=left width="33%" SIZE=1><DIV id=ftn1 style="mso-element: footnote"><P class=MsoFootnoteText style="MARGIN: 0cm 0cm 0pt"><A style="mso-footnote-id: ftn1" href="https://www.otciq.com/otciq/member/#_ftnref1" name=_ftn1><span class=MsoFootnoteReference><span style="FONT-SIZE: 9pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 10.0pt"><span style="mso-special-character: footnote"><span class=MsoFootnoteReference><span style="FONT-SIZE: 9pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-AU; mso-fareast-language: EN-AU; mso-bidi-language: AR-SA; mso-bidi-font-size: 10.0pt">[1]</span></span></span></span></span></A><span style="FONT-SIZE: 7pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 8.0pt"> The Anti-Money Laundering and Counter-Terrorism Financing Act 2006 received Royal Assent on 12 December 2006 and represents the first tranche of reforms to strengthen Australia&#8217;s anti-money laundering and counter-terrorism financing system</span><span style="FONT-SIZE: 9pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 10.0pt">. </span><span style="FONT-FAMILY: 'Arial','sans-serif'"><o:p></o:p></span></P></DIV></DIV></span>]]></description>
<pubDate>Thu, 02 Jul 2009 00:08:07 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=BRVSY&newsId=15549]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Bravura Solutions Ltd.]]></category>
</item>
<item>
<title><![CDATA[Living Cell Technologies Ltd. (LVCLY: Pink Quote) | New Pig Breeding Facility Opens - NZ Diabetes Clinical Trial]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=LVCLY&newsId=15548]]></link>
<description><![CDATA[<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Living Cell Technologies Limited<span style="mso-tab-count: 4">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-outline-level: 1"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><font size=3>COMPANY ANNOUNCEMENT: <span style="COLOR: red"><o:p></o:p></span></font></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-outline-level: 1"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p><font size=3>&nbsp;</font></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><font size=3>Living Cell Technologies Opens New Pig Breeding Facility for <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:country-region w:st="on"><st1:place w:st="on">New Zealand</st1:place></st1:country-region> Diabetes Clinical Trial<o:p></o:p></font></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p><font size=3>&nbsp;</font></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">2 July 2009:<span style="COLOR: red"> </span>Sydney, Australia, Auckland, New Zealand&#8211; Living Cell Technologies Limited (<st1:stockticker w:st="on">ASX</st1:stockticker>: LCT; OTCQX: LVCLY)</span></strong><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"> announced that its new designated pathogen free pig breeding facility in Invercargill, Southland, New Zealand was formally opened by the Mayor of Invercargill, Mr. Tim Shadbolt.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">The facility is designed to meet health regulations for pig herds used as a source of medical grade tissues. The state-of-the-art unit is expected to be commissioned and the pigs transferred in the next few weeks.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Professor <st1:PersonName w:st="on">Bob Elliott</st1:PersonName>, LCT Founder and Medical Director said, &#8220;LCT&#8217;s pigs originate from the sub-Antarctic <st1:place w:st="on"><st1:PlaceName w:st="on">Auckland</st1:PlaceName> <st1:PlaceType w:st="on">Islands</st1:PlaceType></st1:place> and are disease free. The new unit ensures that they remain free of viruses, bacteria and parasites.&#8221;<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">LCT CEO Dr Paul Tan said: &#8220;There are separate maternity and holding units. This upgrades and expands our pig facility to accommodate a sufficient number of pigs to support clinical trials in <st1:country-region w:st="on"><st1:place w:st="on">New Zealand</st1:place></st1:country-region> and internationally over the next two years.&#8221;<span style="mso-spacerun: yes">&nbsp; </span><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">On 19 June 2009 LCT announced that the <st1:country-region w:st="on"><st1:place w:st="on">New Zealand</st1:place></st1:country-region> government had finalised conditions for the diabetes clinical trial that is expected to start within two months.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">DIABECELL<SUP>&#174;</SUP> is designed to normalize blood glucose levels in type 1 diabetes sufferers.<span style="mso-spacerun: yes">&nbsp; </span>DIABECELL<SUP>&#174;</SUP> comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs. <o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Type 1 diabetes occurs when the body's own immune system destroys the insulin-producing cells of the pancreas (called beta cells).<span style="mso-spacerun: yes">&nbsp; </span>Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes.<span style="mso-spacerun: yes">&nbsp; </span>Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations.<span style="mso-spacerun: yes">&nbsp; </span>Current treatment options include multiple daily injections of insulin.<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><v:shapetype id=_x0000_t75 stroked="f" filled="f" path="m@4@5l@4@11@9@11@9@5xe" o:preferrelative="t" o:spt="75" coordsize="21600,21600"><v:stroke joinstyle="miter"></v:stroke><v:formulas><v:f eqn="if lineDrawn pixelLineWidth 0"></v:f><v:f eqn="sum @0 1 0"></v:f><v:f eqn="sum 0 0 @1"></v:f><v:f eqn="prod @2 1 2"></v:f><v:f eqn="prod @3 21600 pixelWidth"></v:f><v:f eqn="prod @3 21600 pixelHeight"></v:f><v:f eqn="sum @0 0 1"></v:f><v:f eqn="prod @6 1 2"></v:f><v:f eqn="prod @7 21600 pixelWidth"></v:f><v:f eqn="sum @8 21600 0"></v:f><v:f eqn="prod @7 21600 pixelHeight"></v:f><v:f eqn="sum @10 21600 0"></v:f></v:formulas><v:path o:connecttype="rect" gradientshapeok="t" o:extrusionok="f"></v:path><o:lock aspectratio="t" v:ext="edit"></o:lock></v:shapetype><v:shape id=_x0000_i1025 style="WIDTH: 173.25pt; HEIGHT: 130.5pt" type="#_x0000_t75"><v:imagedata o:title="100_1298" src="file:///C:\DOCUME~1\debra\LOCALS~1\Temp\msohtml1\01\clip_image001.jpg"></v:imagedata></v:shape><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;</span><v:shape id=_x0000_i1026 style="WIDTH: 174pt; HEIGHT: 130.5pt" type="#_x0000_t75"> <v:imagedata o:title="Thelma 2 Jan09" src="file:///C:\DOCUME~1\debra\LOCALS~1\Temp\msohtml1\01\clip_image003.jpg"></v:imagedata></v:shape><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><span style="mso-spacerun: yes">&nbsp;&nbsp; </span><span style="mso-tab-count: 1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="mso-spacerun: yes">&nbsp;</span></span><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Exterior view of new LCT facility<span style="mso-tab-count: 1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style="mso-spacerun: yes">&nbsp;&nbsp; </span><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="mso-spacerun: yes">&nbsp;</span>LCT&#8217;s <st1:place w:st="on"><st1:PlaceName w:st="on">Auckland</st1:PlaceName> <st1:PlaceType w:st="on">Island</st1:PlaceType></st1:place> pig<o:p></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt 180pt"><span lang=EN-NZ style="FONT-SIZE: 11pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">-Ends- <o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">For further information: <A href="http://www.lctglobal.com/">www.lctglobal.com</A><o:p></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><TABLE class=MsoNormalTable style="BORDER-COLLAPSE: collapse; mso-yfti-tbllook: 480; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-prop-change: ccorcoran 20081001T1119" cellSpacing=0 cellPadding=0 border=0><TBODY><TR style="HEIGHT: 53.55pt; mso-prop-change: ccorcoran 20081001T1119; mso-yfti-irow: 0; mso-yfti-firstrow: yes"><TD style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 5.4pt; BORDER-TOP: #ece9d8; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: #ece9d8; WIDTH: 220.2pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #ece9d8; HEIGHT: 53.55pt; BACKGROUND-COLOR: transparent" vAlign=top width=294><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Dr. <st1:PersonName w:st="on">Paul Tan</st1:PersonName><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Chief Executive Officer<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Mob: 021 608 784 (NZ)<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Tel:+64 9 276 2690<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><A href="mailto:ptan@lctglobal.com">ptan@lctglobal.com</A><o:p></o:p></span></P></TD><TD style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 5.4pt; BORDER-TOP: #ece9d8; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: #ece9d8; WIDTH: 218.9pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #ece9d8; HEIGHT: 53.55pt; BACKGROUND-COLOR: transparent" vAlign=top width=292><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Mr <st1:PersonName w:st="on">John Cowan</st1:PersonName><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Finance &amp; Administration Manager<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Tel: +64 9 276 2690<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><A href="mailto:jcowan@lctglobal.com">jcowan@lctglobal.com</A><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P></TD></TR><TR style="mso-prop-change: ccorcoran 20081001T1119; mso-yfti-irow: 1; mso-yfti-lastrow: yes"><TD style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 5.4pt; BORDER-TOP: #ece9d8; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: #ece9d8; WIDTH: 220.2pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #ece9d8; BACKGROUND-COLOR: transparent" vAlign=top width=294><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Prof. <st1:PersonName w:st="on">Bob Elliott</st1:PersonName><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Medical Director<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Mob: +64 27 292 4177 <o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Tel:+64 9 276 2690<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><A href="mailto:belliott@lctglobal.com">belliott@lctglobal.com</A><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P></TD><TD style="BORDER-RIGHT: #ece9d8; PADDING-RIGHT: 5.4pt; BORDER-TOP: #ece9d8; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 0cm; BORDER-LEFT: #ece9d8; WIDTH: 218.9pt; PADDING-TOP: 0cm; BORDER-BOTTOM: #ece9d8; BACKGROUND-COLOR: transparent" vAlign=top width=292><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Paul Dekkers<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Investor and Media Relations <o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Tel: +612 9237 2800<o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><A href="mailto:pdekkers@bcg.com.au">pdekkers@bcg.com.au</A><o:p></o:p></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 8pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P></TD></TR></TBODY></TABLE><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong style="mso-bidi-font-weight: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><strong><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">About Living Cell Technologies: <A title=http://www.lctglobal.com/ href="http://www.lctglobal.com/">www.lctglobal.com</A> <o:p></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><em><span lang=EN-NZ style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases.<span style="mso-spacerun: yes">&nbsp; </span></span></em><em style="mso-bidi-font-style: normal"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders.<span style="mso-spacerun: yes">&nbsp; </span>For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels.<span style="mso-spacerun: yes">&nbsp; </span>The Company entered clinical trials for its diabetes product in 2007.<span style="mso-spacerun: yes">&nbsp; </span>For the treatment of Parkinson&#8217;s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain.<span style="mso-spacerun: yes">&nbsp; </span>LCT&#8217;s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection.<span style="mso-spacerun: yes">&nbsp; </span>LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.<o:p></o:p></span></em></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none"><strong><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ"><o:p>&nbsp;</o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none"><strong><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">LCT Disclaimer<o:p></o:p></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-layout-grid-align: none"><span lang=EN-NZ style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-ansi-language: EN-NZ">This document contains certain forward-looking statements, relating to LCT&#8217;s business, which can be<span style="mso-spacerun: yes">&nbsp; </span>identified by the use of forward-looking terminology such as &#8220;promising,&#8221; &#8220;plans,&#8221; &#8220;anticipated,&#8221; &#8220;will&#8221;, &#8220;project&#8221;, &#8220;believe&#8221;, &#8220;forecast&#8221;, &#8220;expected&#8221;, &#8220;estimated&#8221;, &#8220;targeting&#8221;, &#8220;aiming&#8221;, &#8220;set to,&#8221; &#8220;potential,&#8221; &#8220;seeking to,&#8221; &#8220;goal,&#8221; &#8220;could provide,&#8221; &#8220;intends,&#8221; &#8220;is being developed,&#8221; &#8220;could be,&#8221; &#8220;on track,&#8221; or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA&#8217;s and other health authorities&#8217; requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management&#8217;s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.<o:p></o:p></span></P>]]></description>
<pubDate>Wed, 01 Jul 2009 19:41:54 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=LVCLY&newsId=15548]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Living Cell Technologies Ltd.]]></category>
</item>
<item>
<title><![CDATA[ReGen Therapeutics Plc (REGUY: Pink Quote) | Notice of Annual General Meeting]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=REGUY&newsId=15544]]></link>
<description><![CDATA[<font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>1</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. It contains the</P><P align=left>resolutions to be voted on at the Company&#8217;s Annual General Meeting to be held on 21 July 2009. If you</P><P align=left>are in any doubt as to the action you should take, you are recommended to seek your own personal</P><P align=left>financial advice from your stockbroker, bank manager, solicitor, accountant or other independent</P><P align=left>financial adviser who is authorised under the Financial Services and Markets Act 2000.</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>If you have sold or otherwise transferred all your ordinary shares in the Company, please forward this document</P><P align=left>and the form of proxy for use in relation to the Annual General Meeting of the Company, as soon as possible</P><P align=left>to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer</P><P align=left>was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some</P><P align=left>of your ordinary shares in the Company, you should consult with the stockbroker, bank or other agent through</P><P align=left>whom the sale or transfer was effected.</P><P align=left>Please see the attached explanatory notes for further details on the resolutions to be proposed at the Annual</P><P align=left>General Meeting.</P></font></font><strong><font face=Univers-Bold size=7><font face=Univers-Bold size=7><P align=left>ReGen Therapeutics Plc</P></strong></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2><P align=left>(incorporated and registered in England and Wales under number 3508592)</P></em></font></font><strong><font face=Univers-Bold><P align=left>NOTICE OF ANNUAL GENERAL MEETING</P></strong></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Notice of the Annual General Meeting of the Company to be held at the offices of Orrick, Herrington &amp;</P><P align=left>Sutcliffe, Tower 42, Level 35, 25 Old Broad Street, London EC2N 1HQ at 11 am on 21 July 2009 is set out at</P><P align=left>the end of this document.</P><P align=left>Whether or not you propose to attend the Annual General Meeting, please complete and submit a proxy form</P><P align=left>in accordance with the instructions printed on the enclosed form. The proxy form must be received not less</P><P align=left>than 48 hours before the time of the holding of the Annual General Meeting.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>2</P></font></font><strong><font face=Univers-Bold size=4><font face=Univers-Bold size=4><P align=left>ReGen Therapeutics Plc</P></strong></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2><P align=left>(incorporated and registered in England and Wales under number 3508592)</P><P align=left>Directors and Company Secretary Registered Office</P></em></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Percy Lomax (Executive Chairman) Suite 306</P><P align=left>Norman Lott (Finance Director and Company Secretary) 73 Watling Street</P><P align=left>Timothy Shilton (Development Director) London</P><P align=left>Martin Small (New Projects Director) EC4M 9BJ</P><P align=left>Peter Garrod (Non-Executive Director)</P></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2><P align=left>To Shareholders and for information purposes only, to holders of options and warrants</P></em></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Dear Shareholder,</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>2009 Annual General Meeting</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>I am pleased to be writing to you with details of the Annual General Meeting (&#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>AGM</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) of ReGen Therapeutics</P><P align=left>Plc (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>Company</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) which we are holding at the offices of Orrick, Herrington &amp; Sutcliffe, Tower 42, Level</P><P align=left>35, 25 Old Broad Street, London, EC2N 1HQ at 11 am on 21 July 2009. The formal Notice of AGM is set out</P><P align=left>on pages 4 to 6 of this document.</P><P align=left>If you would like to vote on the resolutions but cannot come to the AGM, please fill in the proxy form sent to</P><P align=left>you with this document and return it to our registrars, Capita Registrars, as soon as possible. They must</P><P align=left>receive it by no later than 11 am on 19 July 2009.</P><P align=left>There are a number of items of business to which I would like to draw your attention. Full details of these and</P><P align=left>all other resolutions to be proposed are set out in the Explanatory Notes to the resolutions on pages 7 and 8</P><P align=left>of this document.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Re-election of Timothy Shilton and Martin Small</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Timothy Shilton and Martin Small will be submitting themselves for re-election by rotation in accordance with</P><P align=left>the Company&#8217;s Articles of Association.</P><P align=left>Biographical details of each of these Directors are contained on pages 14 to 15 of the Company&#8217;s annual report</P><P align=left>and accounts for the year ended 31 December 2008.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Grant of authority to allot shares and disapply pre-emption rights</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>We announced on 12 June 2009 that we had raised &#163;367,185 this year through private placings in a very</P><P align=left>difficult but improving market. In view of the Company&#8217;s reduced working capital requirements the sums</P><P align=left>raised go a long way to satisfying the Company&#8217;s need for capital until we reach sustainable profitability.</P><P align=left>The existing authorities to allot shares and disapply statutory pre-emption rights which were granted at the</P><P align=left>Company&#8217;s last Extraordinary General Meeting on 26 March 2009 will expire on the conclusion of the</P><P align=left>Company&#8217;s Annual General Meeting. As stated in my last letter to Shareholders on 2 March 2006, the Directors</P><P align=left>would like to be in a position to consider promptly and effect appropriate funding proposals as and when they</P><P align=left>occur. Accordingly, the Directors are now seeking to renew these general authorities.</P><P align=left>The Directors are requesting authority to issue up to 10,000,000 new ordinary shares of 0.01p to facilitate</P><P align=left>future fundraisings and/or acquisitions of complementary businesses, which represents approximately 37%</P><P align=left>of the current issued share capital of the Company. In addition, the Directors are seeking renewal of their</P><P align=left>general authorities to issue up to 1,352,000 new ordinary shares of 0.01p each which represents approximately</P><P align=left>5% of the current issued share capital of the Company.</P><P align=left>Accordingly, Shareholder resolutions are being proposed at the AGM for the purpose of (i) granting the</P><P align=left>Directors authority to allot ordinary shares in the amounts and for the purposes discussed above, and</P><P align=left>(ii) disapplying pre-emption rights in connection with such allotments.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>3</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Amendments to the Articles of Association</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>We are also asking Shareholders to approve a number of amendments to our existing Articles of Association,</P><P align=left>primarily to reflect the provisions of the Companies Act 2006. An explanation of the main changes between</P><P align=left>the proposed and the existing Articles of Association is set out on pages 9 to 11 of this document.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Electronic Communications</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>As mentioned above, the Company is seeking to amend its current Articles of Association to permit the</P><P align=left>Company to send or supply documents and information to Shareholders in electronic form and via a website.</P><P align=left>However, whilst it is appropriate to make these amendments at this time, the Company does not currently</P><P align=left>intend to communicate electronically with its Shareholders as the costs of doing so, at least in the short term,</P><P align=left>will be higher than the current costs of providing paper communications. The Company will keep this under</P><P align=left>review on an on-going basis.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Entitlement to Attend and Vote</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>To have the right to attend and vote at the meeting (and also for the purposes of calculating how many votes</P><P align=left>a person may cast) a person must have their name entered on the register of members no later than 6 pm on</P><P align=left>20 July 2009. Changes to entries on the register after this time will be disregarded in determining the rights</P><P align=left>of any person to attend or vote at the meeting.</P><P align=left>Explanatory notes on all the business to be considered at this year&#8217;s AGM appear on pages 7 and 8 of</P><P align=left>this document.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Documents Available for Inspection</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>A copy of the proposed new Articles of Association of the Company and a copy of the existing Articles of</P><P align=left>Association marked to show the changes being proposed in resolution 11 will be available for inspection</P><P align=left>during business hours on any weekday (public holidays excepted) at the registered office of the Company</P><P align=left>from the date of this document until the conclusion of the AGM and at offices of Orrick, Herrington &amp; Sutcliffe,</P><P align=left>Tower 42, Level 35, 25 Old Broad Street, London, EC2N 1HQ from 15 minutes before the AGM until it ends.</P></font></font><strong><em><font face=Univers-BoldOblique size=2><font face=Univers-BoldOblique size=2><P align=left>Important Note</P></em></font></font><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Please note that the Annual General Meeting is to be held on the 35th floor of Tower 42. Security at</P><P align=left>Tower 42 is strict and it can be a lengthy process to clear. If you are planning to attend in person,</P><P align=left>you are therefore advised to arrive in plenty of time, to ensure that you clear security and arrive on the</P><P align=left>35th floor by 11 am.</P><P align=left>Recommendation</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Directors consider that all the resolutions set out in the Notice of AGM are in the best interests of the</P><P align=left>Company and its Shareholders as a whole and recommend that you vote in favour of each of these resolutions,</P><P align=left>as each of the Directors intends to do in respect of his own beneficial holding of shares in the Company which</P><P align=left>in aggregate amount to 1,356,059 ordinary shares of 0.01p each, representing 5.02% of the Company&#8217;s</P><P align=left>issued ordinary share capital as at the date of this document.</P><P align=left>Yours faithfully,</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Percy Lomax</P></strong></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2><P align=left>Executive Chairman</P></em></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>4</P></font></font><strong><font face=Univers-Bold size=7><font face=Univers-Bold size=7><P align=left>ReGen Therapeutics Plc</P></strong></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2><P align=left>(incorporated and registered in England and Wales under number 3508592)</P></em></font></font><strong><font face=Univers-Bold size=4><font face=Univers-Bold size=4><P align=left>Notice of Annual General Meeting</P></font></font><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>NOTICE IS HEREBY GIVEN that theAnnualGeneralMeeting of ReGen Therapeutics Plc (the &#8220;Company&#8221;)</P><P align=left>will be held at the offices of Orrick, Herrington &amp; Sutcliffe, Tower 42, Level 35, 25 Old Broad Street,</P><P align=left>London EC2N 1HQ at 11 am on 21 July 2009 for the following purposes:</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>To consider and, if thought fit, to pass resolutions 1 to 8 (inclusive) as ordinary resolutions:</P><P align=left>1. To receive and adopt the Directors&#8217; Report, the Auditor&#8217;s Report and the Company&#8217;s accounts for the year</P><P align=left>ended 31 December 2008.</P><P align=left>2. To re-appoint Timothy Shilton as a Director of the Company.</P><P align=left>3. To re-appoint Martin Small as a Director of the Company.</P><P align=left>4. To appoint Mazars LLP as Auditor in accordance with section 489 of the Companies Act 2006 to hold</P><P align=left>office until the conclusion of the Annual General Meeting of the Company in 2010.</P><P align=left>5. To authorise the Directors to determine the remuneration of the Auditor.</P><P align=left>6. THAT, in substitution for any existing and unexercised authorities, the Directors be authorised generally</P><P align=left>and unconditionally pursuant to Section 80 of the Companies Act 1985 as amended (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>1985 Act</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) (in</P><P align=left>substitution for all other existing authorities pursuant to Section 80 of the 1985 Act to the extent not</P><P align=left>utilised at the date this resolution is passed) to exercise all the powers of the Company to allot relevant</P><P align=left>securities, provided that the authority conferred by this resolution shall be limited to the allotment of</P><P align=left>relevant securities of the Company up to an aggregate nominal amount of &#163;135.20 such authority (unless</P><P align=left>previously revoked, substituted, varied or renewed) to expire on the conclusion of the Annual General</P><P align=left>Meeting of the Company to be held in 2010 or, if earlier, 15 months after the date on which this resolution</P><P align=left>has been passed, provided that the Company may, before such expiry, make an offer, agreement or other</P><P align=left>arrangement which would or might require relevant securities to be allotted after such expiry and the</P><P align=left>Directors may allot such relevant securities in pursuance of such offer, agreement or other arrangement</P><P align=left>as if the authority conferred hereby had not expired (and in this resolution the expression &#8220;relevant</P><P align=left>securities&#8221; and reference to the allotment of relevant securities shall bear the same respective meanings</P><P align=left>as in section 80 of the 1985 Act).</P><P align=left>7. THAT, in substitution for any existing and unexercised authorities, the Directors be authorised generally</P><P align=left>and unconditionally pursuant to Section 80 of the Companies Act 1985 as amended (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>1985 Act</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) (in</P><P align=left>substitution for all other existing authorities pursuant to Section 80 of the 1985 Act to the extent not</P><P align=left>utilised at the date this resolution is passed) to exercise all the powers of the Company to allot relevant</P><P align=left>securities, provided that the authority conferred by this resolution shall be limited to the allotment of</P><P align=left>relevant securities of the Company up to an aggregate nominal amount of &#163;1,000 pursuant to any</P><P align=left>fundraisings by the Company and/or the acquisition by the Company and/or its subsidiaries of the shares,</P><P align=left>business and/or assets of a company and/or other legal entity, such authority (unless previously revoked,</P><P align=left>substituted, varied or renewed) to expire on the conclusion of the Annual General Meeting of the</P><P align=left>Company to be held in 2010 or, if earlier, 15 months after the date on which this resolution has been</P><P align=left>passed, provided that the Company may, before such expiry, make an offer, agreement or other</P><P align=left>arrangement which would or might require relevant securities to be allotted after such expiry and the</P><P align=left>Directors may allot such relevant securities in pursuance of such offer, agreement or other arrangement</P><P align=left>as if the authority conferred hereby had not expired (and in this resolution the expression &#8220;relevant</P><P align=left>securities&#8221; and reference to the allotment of relevant securities shall bear the same respective meanings</P><P align=left>as in section 80 of the 1985 Act).</P><P align=left>8. That with effect from 00.01 am on 1 October 2009, all provisions in the Memorandum and Articles of</P><P align=left>Association of the Company as to the amount of the Company&#8217;s authorised share capital or setting the</P><P align=left>maximum amount of shares which may be allotted by the Company shall be revoked and be of no further</P><P align=left>force or effect.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>5</P></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>To consider and, if thought fit, to pass resolutions 9 to 11 (inclusive) as special resolutions:</P><P align=left>9. THAT, subject to resolution 6 above being duly passed, in substitution for any existing and unexercised</P><P align=left>authorities, the Directors be and are hereby generally empowered to allot equity securities (within the</P><P align=left>meaning of Section 94(2)) for cash pursuant to the authority conferred by resolution 6 above as if Section</P><P align=left>89(1) of the Companies Act 1985 (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>1985 Act</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) or any pre-emption provisions contained in the</P><P align=left>Company&#8217;s articles of association did not apply to any such allotment, provided that the power conferred</P><P align=left>by this resolution shall be limited to:</P><P align=left>(i) any allotment of equity securities where such securities have been offered (whether by way of</P><P align=left>rights issue, open offer or otherwise) to holders of equity securities in proportion (as nearly as may</P><P align=left>be practicable) to their then holdings of such securities, but subject to the Directors having the right</P><P align=left>to make such exclusions or other arrangements in connection with such offer as they deem</P><P align=left>necessary or expedient to deal with fractional entitlements or legal or practical problems arising in,</P><P align=left>or pursuant to, the laws of any territory or the requirements of any regulatory body or stock exchange</P><P align=left>in any territory or otherwise howsoever; and</P><P align=left>(ii) any other allotment (otherwise than pursuant to sub-paragraph (i) of this resolution 9) of equity</P><P align=left>securities up to an aggregate nominal value of &#163;135.20,</P><P align=left>such authorities and powers (unless previously revoked, substituted, varied or renewed) to expire on the</P><P align=left>earlier to occur of 15 months after the passing of this resolution or the conclusion of the Annual General</P><P align=left>Meeting of the Company to be held in 2010, provided that the Company may prior to such expiry make</P><P align=left>any offer, agreement or other arrangement which would or might require equity securities to be allotted</P><P align=left>after such expiry and the Directors may allot equity securities pursuant to any such offer, agreement or</P><P align=left>other arrangement as if the power hereby conferred had not expired.</P><P align=left>10. THAT, subject to resolution 7 above being duly passed, in substitution for any existing and unexercised</P><P align=left>authorities, the Directors be and are hereby generally empowered to allot equity securities (within the</P><P align=left>meaning of Section 94(2)) for cash pursuant to the authority conferred by resolution 7 above as if Section</P><P align=left>89(1) of the Companies Act 1985 (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>1985 Act</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) or any pre-emption provisions contained in the</P><P align=left>Company&#8217;s Articles of Association did not apply to any such allotment, provided that the power conferred</P><P align=left>by this resolution shall be limited to the allotment of equity securities up to an aggregate nominal value</P><P align=left>of &#163;1,000 pursuant to any fundraisings by the Company and/or the acquisition by the Company and/or its</P><P align=left>subsidiaries of the shares, business and/or assets of a company and/or other legal entity, such authority</P><P align=left>and power (unless previously revoked, substituted, varied or renewed) to expire on the earlier to occur</P><P align=left>of 15 months after the passing of this resolution or the conclusion of the Annual General Meeting of the</P><P align=left>Company to be held in 2010, provided that the Company may prior to such expiry make any offer,</P><P align=left>agreement or other arrangement which would or might require equity securities to be allotted after such</P><P align=left>expiry and the Directors may allot equity securities pursuant to any such offer, agreement or other</P><P align=left>arrangement as if the power hereby conferred had not expired.</P><P align=left>11. THAT:</P><P align=left>(i) the amended Articles of Association produced as a printed document to this meeting and initialled</P><P align=left>by the Chairman for the purposes of identification be adopted as the Articles of Association of the</P><P align=left>Company in substitution for and to the exclusion of the existing Articles of Association; and</P><P align=left>(ii) with effect from 00.01 am on 1 October 2009 the Articles of Association of the Company be</P><P align=left>amended by (a) deleting all the provisions of the Company&#8217;s Memorandum of Association, which,</P><P align=left>by virtue of Section 28 of the Companies Act 2006, are to be treated as part of the Company&#8217;s</P><P align=left>Articles of Association, and (b) inserting a new article 2A stating that &#8220;The liability of the members</P><P align=left>is limited&#8221;.</P><P align=left>BY ORDER OF THE BOARD</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Percy Lomax </strong></font></font><em><font face=Univers-LightOblique size=2><font face=Univers-LightOblique size=2>Registered Office:</P><P align=left>Executive Chairman </em></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>Suite 306</P><P align=left>73 Watling Street</P><P align=left>26 June 2009 London</P><P align=left>EC4M 9BJ</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>6</P></font></font><strong><font face=Univers-Bold size=1><font face=Univers-Bold size=1><P align=left>Notes:</P></strong></font></font><font face=Univers-Light size=1><font face=Univers-Light size=1><P align=left>1. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, only those members registered in the</P><P align=left>register of members of the Company as at 6 pm on 20 July 2009 shall be entitled to attend and vote at this Annual</P><P align=left>General Meeting in respect of the number of shares registered in their name at that time. Changes to entries on the</P><P align=left>relevant register of securities after such time shall be disregarded in determining the rights of any person to attend</P><P align=left>or vote at this Annual General Meeting.</P><P align=left>2. Any member who is entitled to attend and vote at this Annual General Meeting is entitled to appoint one or more</P><P align=left>proxies to exercise all or any of his/her rights to attend, speak and vote at the meeting. To appoint more than one</P><P align=left>proxy, additional Forms of Proxy may be obtained by contacting the Registrars or you may photocopy the form. If you</P><P align=left>appoint more than one proxy, each proxy must be appointed to exercise the rights attached to a different share or</P><P align=left>shares held by you. Please indicate in the box next to the proxy holder&#8217;s name the number of shares in relation to</P><P align=left>which they are authorised to act as your proxy. Please also indicate by ticking the box provided if the proxy instruction</P><P align=left>is one of multiple instructions being given. A proxy need not be a member of the Company. Completion and return</P><P align=left>of the Form of Proxy will not preclude a member from attending and voting at this Annual General Meeting. If you</P><P align=left>have appointed a proxy and attend the meeting in person, your proxy appointment will automatically be terminated.</P><P align=left>3. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment</P><P align=left>submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of</P><P align=left>the joint holders appear in the Company&#8217;s register of members in respect of the joint holding (the first-named being</P><P align=left>the most senior).</P><P align=left>4. If you submit more than one valid proxy appointment in respect of the same shares, the appointment received last</P><P align=left>before the latest time for the receipt of proxies will take precedence.</P><P align=left>5. In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a &#8220;CREST</P><P align=left>Proxy Instruction&#8221;) must be properly authenticated in accordance with CRESTCo&#8217;s specifications and must contain</P><P align=left>the information required for such instructions, as described in the CREST Manual. The message must be transmitted</P><P align=left>so as to be received by the issuer&#8217;s agent (ID RA10) by the latest time(s) for receipt of proxy appointments specified</P><P align=left>in the notice of meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the</P><P align=left>timestamp applied to the message by the CREST Applications Host) from which the issuer&#8217;s agent is able to retrieve</P><P align=left>the message by enquiry to CREST in the manner prescribed by CREST. CREST members and, where applicable,</P><P align=left>their CREST sponsors or voting service providers should note that CRESTCo does not make available special</P><P align=left>procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in</P><P align=left>relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or,</P><P align=left>if the CREST member is a CREST personal member or sponsored member or has appointed a voting service</P><P align=left>provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary</P><P align=left>to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection,</P><P align=left>CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular,</P><P align=left>to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The</P><P align=left>Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the</P><P align=left>Uncertificated Securities Regulations 2001.</P><P align=left>6. A Form of Proxy is enclosed which to be effective must be completed, signed and received by the Company&#8217;s</P><P align=left>registrars, Capita Registrars Proxies, PO Box 25, Beckenham, Kent BR3 4BR, no later than 48 hours before the time</P><P align=left>of the Annual General Meeting. You can only appoint a proxy using the procedures set out in these notes and in the</P><P align=left>notes to the enclosed Form of Proxy.</P><P align=left>7. In order to facilitate voting by corporate representatives at the Annual General Meeting, arrangements will be put in</P><P align=left>place at the meeting so that (i) if a corporate member appointed the Chairman of the meeting as its corporate</P><P align=left>representative with instructions to vote on a poll in accordance with the directions of all of the other corporate</P><P align=left>representatives for that member at the meeting, then on a poll those corporate representatives will give voting</P><P align=left>directions to the Chairman and the Chairman will vote (or withhold a vote) as corporate representative in accordance</P><P align=left>with those directions; and (ii) if more than one corporate representative for the same corporate member attends the</P><P align=left>meeting but the corporate member has not appointed the Chairman of the meeting as its corporate representative,</P><P align=left>a designated corporate representative will be nominated, from those corporate representatives who attend, who will</P><P align=left>vote on a poll and the other corporate representatives will give voting directions to that designated corporate</P><P align=left>representative. Corporate members are referred to the guidance issued by the Institute of Chartered Secretaries and</P><P align=left>Administrators on proxies and corporate representatives &#8211; www.icsa.org.uk &#8211; for further details of this procedure.</P><P align=left>The guidance includes a sample form of representation letter if the Chairman is being appointed as described</P><P align=left>in (i) above.</P><P align=left>8. In accordance with Section 325 of the Companies Act 2006, the right to appoint proxies does not apply to persons</P><P align=left>nominated to receive information rights under Section 146 of the Companies Act 2006. Persons nominated to</P><P align=left>receive information rights under Section 146 of the Companies Act 2006 who have been sent a copy of this notice</P><P align=left>of meeting are hereby informed, in accordance with Section 149(2) of the Companies Act 2006, that they may have</P><P align=left>a right under an agreement with the registered member by whom they were nominated to be appointed, or to have</P><P align=left>someone else appointed, as a proxy for this meeting. If they have no such right, or do not wish to exercise it, they</P><P align=left>may have a right under such an agreement to give instructions to the member as to the exercise of voting</P><P align=left>rights. Nominated persons should contact the registered member by whom they were nominated in respect of</P><P align=left>these arrangements</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>7</P></font></font><strong><font face=Univers-Bold size=4><font face=Univers-Bold size=4><P align=left>EXPLANATORY NOTES</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The notes on the following pages give an explanation of the proposed resolutions.</P><P align=left>Resolutions 1 to 8 are proposed as ordinary resolutions. This means that for each of those resolutions to be</P><P align=left>passed, more than half of the votes cast must be in favour of the resolution. Resolutions 9 to 11 are proposed</P><P align=left>as special resolutions. This means that for each of those resolutions to be passed, at least three-quarters of</P><P align=left>the votes cast must be in favour of the resolution.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>ANNUAL REPORT AND ACCOUNTS (RESOLUTION 1)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Directors are required to lay before the Company at this AGM the accounts of the Company for the</P><P align=left>financial year ended 31 December 2008, the report of the Directors and the report of the Company&#8217;s Auditors</P><P align=left>on those accounts.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>RE-ELECTION OF DIRECTORS (RESOLUTIONS 2 AND 3)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Timothy Shilton and Martin Small will be submitting themselves for re-election by rotation in accordance with</P><P align=left>the Company&#8217;s current articles of association (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>Current Articles</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;).</P><P align=left>Biographical details of each of these Directors are contained on pages 14 to 15 of the Company&#8217;s annual report</P><P align=left>and accounts for the year ended 31 December 2008.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>APPOINTMENT OF AUDITORS (RESOLUTION 4)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Company is required to appoint auditors at each general meeting at which accounts are laid, to hold office</P><P align=left>until the next such meeting. Resolution 4 proposes the appointment of Mazars LLP as Auditors of the Company.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>REMUNERATION OF AUDITORS (RESOLUTION 5)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Resolution 5 authorises the Directors to determine the Auditors&#8217; remuneration for the ensuing year.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>AUTHORITY TO ALLOT ORDINARY SHARES (RESOLUTIONS 6 AND 7)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Under section 80 of the Companies Act 1985, Directors require Shareholders&#8217; authority for allotment of shares.</P><P align=left>Shareholders last granted such general authority to the Directors at the Extraordinary General Meeting of the</P><P align=left>Company held in March 2009. Such authority will expire at the end of this AGM.</P><P align=left>In addition, Resolution 6 will be proposed as an ordinary resolution, to authorise the Directors to generally allot</P><P align=left>up to 1,352,000 new ordinary shares of 0.01p each which represents approximately 5% of the current issued</P><P align=left>share capital of the Company.</P><P align=left>Resolution 7 will be proposed as an ordinary resolution, to authorise the Directors to allot up to 10,000,000</P><P align=left>new ordinary shares of 0.01p specifically pursuant to any fundraisings by the Company and/or the acquisition</P><P align=left>by the Company and/or its subsidiaries of the shares, business and/or assets of a company and/or other legal</P><P align=left>entity, which represents approximately 37% of the current issued share capital of the Company.</P><P align=left>These authorities will expire on the earlier of 15 months after the passing of the resolutions or on the conclusion</P><P align=left>of the AGM of the Company to be held in 2010.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>REMOVAL OF AUTHORISED SHARE CAPITAL (RESOLUTION 8)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Under the Companies Act 2006, the requirement for a company to have an authorised share capital is abolished</P><P align=left>from 1 October 2009. However, under the Companies Act 2006 (Commencement No. 8, Transitional Provisions</P><P align=left>and Savings) Order 2008, on this date any existing provisions in the Company&#8217;s memorandum of association</P><P align=left>are treated as being part of the Company&#8217;s articles. In order to allow the Company to take advantage of the</P><P align=left>removal of the requirement for an authorised share capital, resolution 8 asks Shareholders to consent to the</P><P align=left>removal of this provision as required by the Companies Act 2006 (Commencement No. 8, Transitional</P><P align=left>Provisions and Savings) Order 2008. The allotment of shares by the Board will remain subject to the authorities</P><P align=left>granted under resolution(s) 6 and 7 (and/or any subsequent authority).</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>8</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>AUTHORITY TO ALLOT ORDINARY SHARES FOR CASH (RESOLUTIONS 9 AND 10)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Under section 89 of the Companies Act 1985, if the Directors wish to allot any of the unissued ordinary shares</P><P align=left>for cash they must in the first instance offer them to existing ordinary Shareholders in proportion to their</P><P align=left>ordinary shareholdings. There may be occasions, however, when the Directors will need the flexibility to</P><P align=left>finance business opportunities by the issue of ordinary shares without a pre-emptive offer to existing ordinary</P><P align=left>Shareholders. Shareholders last granted authorities to the Directors to disapply pre-emptive rights at the</P><P align=left>Extraordinary General Meeting of the Company held in March 2009. Such authorities will expire at the end of</P><P align=left>this AGM and resolutions 9 and 10 seek to renew them.</P><P align=left>Subject to the passing of resolution 6, resolution 9 seeks to generally authorise the Directors to allot up to</P><P align=left>1,352,000 new ordinary shares of 0.01p on a non pre-emptive basis. Such authority would represent</P><P align=left>approximately 5% of the current issued share capital of the Company.</P><P align=left>In addition, subject to the passing of resolution 7, resolution 10 seeks to authorise the Directors to allot up to</P><P align=left>10,000,000 new ordinary shares of 0.01p on a non pre-emptive basis specifically pursuant to any fundraisings</P><P align=left>by the Company and/or the acquisition by the Company and/or its subsidiaries of the shares, business and/or</P><P align=left>assets of a company and/or other legal entity. Such authority would represent approximately 37% of the</P><P align=left>current issued share capital of the Company.</P><P align=left>These authorities will expire on the earlier of 15 months after the passing of the resolutions or on the conclusion</P><P align=left>of the AGM of the Company to be held in 2010.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY (RESOLUTION 11)</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>It is proposed in resolution 11 to adopt new Articles of Association (the &#8220;</font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2>New Articles</strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2>&#8221;) in order to update</P><P align=left>the Company&#8217;s Current Articles primarily to take account of changes in company law brought about by the</P><P align=left>Companies Act 2006. Copies of the Current Articles and proposed New Articles (and a comparison document</P><P align=left>showing all the proposed changes to the Articles) are available for inspection during normal business hours at</P><P align=left>the registered office of the Company until the date of this AGM or upon request from the Company Secretary.</P><P align=left>Copies will be available at least 15 minutes prior to and during the AGM.</P><P align=left>The material differences between the Current Articles and the proposed New Articles are summarised below.</P><P align=left>Changes of a minor, conforming or purely technical nature, and also some minor changes which merely reflect</P><P align=left>changes made by the Companies Act 2006, have not been mentioned specifically.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>9</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>Summary of principal changes to the Company&#8217;s Articles of Association:</P><P align=left>1. The Company&#8217;s objects</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The provisions regulating the operations of the Company are currently set out in the Company&#8217;s</P><P align=left>Memorandum and Articles of Association. The Company&#8217;s Memorandum contains, among other things,</P><P align=left>the objects clause which sets out the scope of the activities the Company is authorised to undertake.</P><P align=left>This is drafted to give a wide scope.</P><P align=left>The Companies Act 2006 significantly reduces the constitutional significance of a company&#8217;s</P><P align=left>memorandum. The Companies Act 2006 provides that a memorandum will record only the names of</P><P align=left>subscribers and the number of shares each subscriber has agreed to take in the company. Under the</P><P align=left>Companies Act 2006 the objects clause and all other provisions which are currently contained in a</P><P align=left>company&#8217;s memorandum, for existing companies at 1 October 2009, will be deemed to be contained in</P><P align=left>a company&#8217;s articles of association but the Company can remove these provisions by special resolution.</P><P align=left>Further the Companies Act 2006 states that unless a company&#8217;s articles provide otherwise, a company&#8217;s</P><P align=left>objects are unrestricted. This abolishes the need for companies to have objects clauses. For this reason</P><P align=left>the Company is proposing to remove its objects clause together with all other provisions of its</P><P align=left>Memorandum which, by virtue of the Companies Act 2006, are to be treated as forming part of the</P><P align=left>Company&#8217;s Articles of Association as of 1 October 2009. Resolution 11 (ii) confirms the removal of these</P><P align=left>provisions for the Company. As the effect of this resolution will be to remove the statement currently in</P><P align=left>the Company&#8217;s Memorandum of Association regarding limited liability, the New Articles also contain an</P><P align=left>express statement regarding the limited liability of the Shareholders.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>2. Articles Which Duplicate Statutory Provisions</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Provisions in the Current Articles which replicate provisions contained in the Companies Act 2006 are in</P><P align=left>the main amended to bring them into line with the Companies Act 2006.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>3. Change of name</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Currently, a company can only change its name by special resolution. Under the Companies Act 2006 a</P><P align=left>company will be able to change its name by other means provided for by its articles of association. To</P><P align=left>take advantage of this provision, the New Articles enable the Directors to pass a resolution to change the</P><P align=left>Company&#8217;s name with effect from 1 October 2009.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>4. Redeemable shares</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>At present if a company wishes to issue redeemable shares, it must include in its articles the terms and</P><P align=left>manner of redemption. The Companies Act 2006 enables Directors to determine such matters instead</P><P align=left>provided they are so authorised by the articles. The New Articles contain such an authorisation which will</P><P align=left>take effect from 1 October 2009. The Company has no plans to issue redeemable shares but if it did so</P><P align=left>the Directors would need Shareholders&#8217; authority to issue new shares in the usual way.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>5. Use of seals</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The New Articles provide an alternative option for execution of documents (other than share certificates).</P><P align=left>Under the New Articles, when the seal is affixed to a document it may be signed by one authorised</P><P align=left>person in the presence of a witness, whereas previously the requirement was for signature by either a</P><P align=left>Director and the Secretary or two Directors or such other person or persons as the Directors may approve.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>6. Suspension of registration of share transfers</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Current Articles permit the Directors to suspend the registration of transfers. Under the Companies</P><P align=left>Act 2006 share transfers must be registered as soon as practicable. The power in the Current Articles to</P><P align=left>suspend the registration of transfers is inconsistent with this requirement. Accordingly, this power has</P><P align=left>been removed in the New Articles.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>7. Vacation of office by Directors</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Current Articles specify the circumstances in which a Director must vacate office. The New Articles</P><P align=left>update these provisions to reflect the approach taken on mental and physical incapacity in the model</P><P align=left>articles for public companies produced by the Department for Business, Enterprise and Regulatory Reform.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>10</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>8. Variation of Class Rights</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Current Articles contain provisions regarding the variation of class rights. The proceedings and</P><P align=left>specific quorum requirements for a meeting convened to vary class rights are contained in the Companies</P><P align=left>Act 2006. The relevant provisions have therefore been removed in the New Articles.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>9. Convening Extraordinary and Annual General Meetings</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The provisions in the Current Articles dealing with the convening of general meetings and the length of</P><P align=left>notice required to convene general meetings are being removed in the New Articles because the relevant</P><P align=left>matters are provided for in the Companies Act 2006. In particular an Extraordinary General Meeting to</P><P align=left>consider a special resolution can be convened on 14 days&#8217; notice whereas previously 21 days notice was</P><P align=left>required. In addition, in line with the Companies Act 2006, references to an &#8220;Extraordinary General</P><P align=left>Meeting&#8221; of the Company will now be replaced with references to a &#8220;General Meeting&#8221;.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>10. Votes of Members</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Under the Companies Act 2006 proxies are entitled to vote on a show of hands whereas under the</P><P align=left>Current Articles proxies are only entitled to vote on a poll. The time limits for the appointment or</P><P align=left>termination of a proxy appointment have been altered by the Companies Act 2006 so that the articles of</P><P align=left>association cannot provide that they should be received more than 48 hours before the meeting or in the</P><P align=left>case of a poll taken more than 48 hours after the meeting, more than 24 hours before the time for the</P><P align=left>taking of a poll, with weekends and bank holidays being permitted to be excluded for this purpose.</P><P align=left>Multiple proxies may be appointed provided that each proxy is appointed to exercise the rights attached</P><P align=left>to a different share held by the Shareholder. The New Articles reflect all of these new provisions.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>11. Conflicts of Interest</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Companies Act 2006 sets out Directors&#8217; general duties which largely codify the existing law but with</P><P align=left>some changes. Under the Companies Act 2006 a Director must avoid a situation where he has, or can</P><P align=left>have, a direct or indirect interest that conflicts, or possibly may conflict with the Company&#8217;s interests.The</P><P align=left>requirement is very broad and could apply, for example, if a Director becomes a Director of another</P><P align=left>company or a trustee of another organisation. The Companies Act 2006 allows Directors of public</P><P align=left>companies to authorise conflicts and potential conflicts, where appropriate, where the articles of</P><P align=left>association contain a provision to this effect. The Companies Act 2006 also allows the articles of</P><P align=left>association to contain other provisions for dealing with Directors&#8217; conflicts of interest to avoid a breach</P><P align=left>of duty. The New Articles give the Directors authority to approve such situations and to include other</P><P align=left>provisions to allow conflicts of interest to be dealt with in a similar way to the current position.</P><P align=left>There are safeguards which will apply when Directors decide whether to authorise a conflict or potential</P><P align=left>conflict. Only Directors who have no interest in the matter being considered will be able to take the</P><P align=left>relevant decision and the Directors will be able to impose limits or conditions when giving authorisation</P><P align=left>if they think this is appropriate.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>12. Records to be Kept</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The provision in the Current Articles requiring the Board to keep accounting records has been removed</P><P align=left>as this requirement is contained in the Companies Act 2006.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>13. Distribution of Assets Otherwise than in Cash</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Current Articles contain provisions dealing with the distribution of assets in kind in the event of the</P><P align=left>Company going into liquidation. These provisions have been removed in the New Articles on the grounds</P><P align=left>that a provision about the powers of liquidators is a matter for insolvency law rather than the Articles and</P><P align=left>that the Insolvency Act 1986 confers powers on the liquidator which would enable it to do what is</P><P align=left>envisaged by the Current Articles.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>14. Provision for Employees on Cessation of Business</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Companies Act 2006 provides that the powers of the Directors to make provision for a person</P><P align=left>employed or formerly employed by the Company in connection with the cessation or transfer to any</P><P align=left>person of the whole or part of the undertaking of the Company, may be exercised by the Directors or by</P><P align=left>the Company in a general meeting. However, if the power is to be exercised by the Directors, the Articles</P><P align=left>of Association must include a provision to this effect. The New Articles provide that the Directors may</P><P align=left>exercise this power.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>11</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>15. Directors&#8217; indemnities and Loans to Fund Expenditure</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>The Companies Act 2006 has in some areas widened the scope of the powers of a company to indemnify</P><P align=left>Directors and to fund expenditure incurred in connection with certain actions against Directors. In particular,</P><P align=left>a Company that is a trustee of an occupational pension scheme can now indemnify a Director against</P><P align=left>liability incurred in connection with the Company&#8217;s activities as trustee of the scheme. In addition, the</P><P align=left>existing exemption allowing a Company to provide money for the purpose of funding a Director&#8217;s defence</P><P align=left>in court proceedings now expressly covers regulatory proceedings and applies to associated companies.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>16. Ordinary and Special Business</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>As the Listing Rules of the UK Listing Authority no longer refer to a distinction between ordinary business</P><P align=left>and special business we do not consider it to be appropriate that the Current Articles continue to make</P><P align=left>such a distinction in addition to the distinction between ordinary and special resolutions. The provision in</P><P align=left>the Current Articles containing a list of resolutions which are deemed to be ordinary business at an</P><P align=left>Annual General Meeting has therefore been removed in the New Articles.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>17. Electronic Communications</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Provisions of the Companies Act 2006 which came into force in January 2007 enable companies to</P><P align=left>communicate with members by electronic and/or website communications. The New Articles continue to</P><P align=left>allow communications to members in electronic form and, in addition, they also permit the Company to</P><P align=left>take advantage of the new provisions relating to website communications. The Company will notify the</P><P align=left>member (either in writing, or by other permittedmeans) when a relevant document or information is placed</P><P align=left>on the website and a member can always request a hard copy version of the document or information.</P></font></font><strong><font face=Univers-Bold size=2><font face=Univers-Bold size=2><P align=left>18. General</P></strong></font></font><font face=Univers-Light size=2><font face=Univers-Light size=2><P align=left>Generally the opportunity has been taken to bring clearer language into the New Articles and in some</P><P align=left>areas to conform the language of the New Articles with that used in the model articles for public</P><P align=left>companies produced by the Department for Business, Enterprise and Regulatory Reform.</P></font></font><font face=HelveticaNeue-Roman size=2><font face=HelveticaNeue-Roman size=2><P align=left>12</P></font></font>]]></description>
<pubDate>Wed, 01 Jul 2009 06:25:56 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=REGUY&newsId=15544]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[ReGen Therapeutics Plc]]></category>
</item>
<item>
<title><![CDATA[Diamyd Medical AB (DMYDY: Pink Quote) | Important progress for Diamyd Medical during the third quarter]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DMYDY&newsId=15541]]></link>
<description><![CDATA[<em>Diamyd Medical&#8217;s President and CEO comments in the company&#8217;s interim report today on several significant advances during the period, including the positive development of the company&#8217;s Phase III program. </em><br><br>&#8220;I&#8217;m very pleased with how the operations has developed this quarter,&#8221; says Elisabeth Lindner, President and CEO of Diamyd Medical. &#8220;Patient recruitment for the European Phase III study is very successful. Now when we have also received approval to include children from age 10 in the US, we can further accelerate the recruitment," Lindner continues. <br><br>Diamyd Medical announced during the third quarter that more than half of the patients had been included in the European Phase III study. After the end of the period, the FDA has approved the inclusion of children from age 10 in the US study. The company can now contract more pediatric clinics and further accelerate patient recruitment.<br><br>During the period, Diamyd Medical also reported that the Swedish Medical Products Agency approved a Phase II study of the Diamyd&#174; vaccine with the objective to prevent or delay the development of type 1 diabetes in children at high risk of developing the disease. <br><br><strong><br>For additional information, please contact: </strong><br>Elisabeth Lindner, President and CEO, Diamyd Medical AB (publ.) <br>Tel: +46 (0)8 661 0026 <br><strong><br>For pictures and press material, please contact: </strong><br>Alexandra Fleetwood, Director Communications, Diamyd Medical AB (publ.), alexandra.fleetwood@diamyd.com <br>Tel: +46 (0)8 661 0026 <br><strong><br><br>About Diamyd Medical </strong><br>Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd&#174; for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company currently has three clinical-phase products. <br><br>Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the company's website: www.diamyd.com. <br><br>This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements. <br><br><br>Diamyd Medical AB (publ.) <br>Linn&#233;gatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68 <br>E-mail: info@diamyd.com. VAT no: SE556530-142001. <br>(www.omxnordicexchange.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)]]></description>
<pubDate>Wed, 01 Jul 2009 05:24:44 EDT</pubDate>
<guid isPermaLink="false"><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=DMYDY&newsId=15541]]></guid>
<author><![CDATA[Pink OTC Markets - News, Filings & Corporate Actions]]></author>
<category><![CDATA[Diamyd Medical AB]]></category>
</item>
<item>
<title><![CDATA[Gold One International Ltd. (GLDZY: Pink Quote) | Twin Hills Project sold for $A 1.75 million cash]]></title>
<link><![CDATA[http://www.pinksheets.com/pink/quote/quote.jsp?symbol=GLDZY&newsId=15540]]></link>
<description><![CDATA[<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center" align=center><strong><span style="text-decoration: underline;"><span style="FONT-FAMILY: 'Tahoma','sans-serif'; mso-bidi-font-size: 12.0pt"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><span style="TEXT-DECORATION: none"><font size=3>&nbsp;</font></span></o:p></span></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><strong><span style="text-decoration: underline;"><span style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'">Twin Hills Project sold for $A 1.75 million cash<o:p></o:p></span></span></strong></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><span style="text-decoration: underline;"><span style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'"><o:p><span style="TEXT-DECORATION: none">&nbsp;</span></o:p></span></span></P><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><strong><span style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'">Johannesburg, South Africa, 1 July 2009. Gold One International (ASX: GDO, JSE: GDO)</span></strong><span style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'; mso-ansi-language: EN-GB; mso-bidi-font-weight: bold"> <span lang=EN-GB>is pleased </span></span><span lang=EN-GB style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'; mso-ansi-language: EN-GB">to </span><span style="FONT-SIZE: 11pt; FONT-FAMILY: 'Tahoma','sans-serif'">announce that it has sold its Twin Hills project in North Queensland to North Queensland Metals Limited (ASX: NQM) and Heemskirk Consolidated Limited (ASX: HSK) (in proportions of 60% and 40